We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Frontida BioPharm Inc. has completed a facility expansion to its oral solid dose manufacturing operations with the commissioning of a Highly Potent Compound Contract Manufacturing Suite.